DBV Technologies reported $461K in Interest Expense on Debt for its fiscal quarter ending in March of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Alnylam Pharmaceuticals USD -84.37M 166.42M Sep/2026
Amarin USD 3K 5K Dec/2024
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
BioMarin Pharmaceutical USD 55.63M 7.67M Sep/2026
DBV Technologies USD 461K 323.71K Mar/2025
Galectin Therapeutics USD 1.27M 220K Jun/2024
Halozyme Therapeutics USD 6.04M 457K Sep/2026
Incyte USD 605K 23K Sep/2026
Insmed USD 20.41M 1.57M Sep/2026
Ionis Pharmaceuticals USD 4M 14M Sep/2026
Neurocrine Biosciences USD 300K 2.6M Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Ultragenyx Pharmaceutical USD 20M 2M Sep/2026
United Therapeutics USD 2.9M 0 Sep/2026